Abstract
The present study was designed to investigate the neuroprotective effect of selegiline on 3-nitropropionic acid (3-NP)-induced neurotoxicity. Selegiline was intraperitoneally injected at doses 2.5, 5, and 10 mg/kg, 3 days prior to and continued daily, 30 min before 3-NP administration. 3-NP (20 mg/kg, i.p.) was administered for four consecutive days. 3-NP-treated rats exhibited PPI deficits, locomotor hypoactivity, increased striatal and cortical lipid peroxidation, and reduced respective glutathione (GSH) levels as well as catalase and superoxide dismutase (SOD) activities. Changes in the level of the apoptotic regulatory gene expressions were demonstrated as increased striatal and cortical caspase-3 and Bax and decreased respective Bcl2. The two higher dose levels of selegiline (5 and 10 mg/kg) significantly increased locomotor activity, improved prepulse inhibition (PPI), reduced striatal and cortical lipid peroxidation, caspase-3, and Bax, and increased GSH level, catalase, and superoxide dismutase activities and Bcl2 expression. Selegiline at dose 2.5 mg/kg could only reverse some of the manifestations of 3-NP-induced neurotoxicity. Histological examination further affirmed the neuroprotective effect of the higher dose levels of selegiline against 3-NP-induced toxicity. Taken together, these results suggest that selegiline could attenuate 3-NP-induced neurotoxicity. This can be attributed to, at least partly, its antioxidant and antiapoptotic effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
27 June 2023
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1007/s00210-023-02600-8
Abbreviations
- ATP:
-
Adenosine triphosphate
- 3-NP:
-
3-nitropropionic acid
- HD:
-
Huntington’s disease
- GABA:
-
Gamma aminobutyric acid
- GSH:
-
Reduced glutathione
- MDA:
-
Malondialdehyde
- MAO-B:
-
Monoamine oxidase B
- PPI:
-
Prepulse inhibition
- SOD:
-
Superoxide dismutase
References
Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126. doi:10.1016/S0076-6879(84)05016-3
Ahuja M, Bishnoi M, Chopra K (2008) Protective effect of minocycline, a semi-synthetic second generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology 244:111–122. doi:10.1016/j.tox.2007.11.003
Al Mutairy A, Al Kadasah S, Elfaki I, Arshaduddin M, Malik D, Al Moutaery K (2010) Trolox ameliorates 3-nitropropionic acid-induced neurotoxicity in rats. Neurotoxicol Teratol 32:226–233. doi:10.1016/j.ntt.2009.09.003
Antonawich FJ, Fiore-Marasa SM, Parker CP (2002) Modulation of apoptotic regulatory proteins and early activation of cytochrome C following systemic 3-nitropropionic acid administration. Brain Res Bull 57:647–649. doi:10.1016/S0361-9230(01)00761-4
Bancroft J, Stevens A (1996) Theory and practice of histological techniques, 4th edn. Churchill Livingstone, Edinburgh, p 766
Beal MF (1996) Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 6:661–666
Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181–4192
Bialik S, Cryns VL, Drincic A, Miyata S, Wollowick AL, Srinivasan A, Kitsis RN (1999) The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 85:403–414
Borlongan CV, Koutouzis TK, Sanberg PR (1997) 3-Nitropropionic acid animal model and Huntington's disease. Neurosci Biobehav Rev 21:289–293
Bowyer JF, Clausing P, Schmued L, Davies DL, Binienda Z, Newport GD (1996) Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum. Brain Res 712:221–229. doi:10.1016/0006-8993(95)01417-9
Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 92:7105–7109
Brouillet E, Guyot MC, Mittoux V, Altairac S, Conde F, Palfi S, Hantraye P (1998) Partial inhibition of brain succinate dehydrogenase by 3- nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 70:794–805. doi:10.1046/j.1471-4159.1998.70020794.x
Browne SE, Beal MF (2004) The energetics of Huntington's disease. Neurochem Res 29:531–546
Buchwalow IB, Böcker W (2010) Immunohistochemistry: basics and methods, (1st ed), Springer Science & Business Media USA pp. 156. doi:10.1007/978-3-642-04609-4
Buuse MV, Eikelis N (2001) Estrogen increases prepulse inhibition of acoustic startle in rats. Eur J Pharmacol 425:33–41. doi:10.1016/S0014-2999(01)01139-6
Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (−)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517–517. doi:10.1016/0024-3205(91)90466-O
Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neural 26:689–690. doi:10.1002/ana.410260518
Coles CJ, Edmondson DE, Singer TP (1979) Inactivation of succinate dehydrogenase by 3-nitropropionate. J Biol Chem 254:5161–5167
Curzon P, Zhang M, Radek RJ, Fox JB (2009) The behavioral assessment of sensorimotor processes in the mouse: acoustic startle, sensory gating, locomotor activity, rotarod and beam walking. In: Buccafusco JJ (ed) Methods of behavior analysis in neuroscience, 2nd edn. CRC Press, Boca Raton Chapter 8
Ebadi M, Sharma S, Shavali S, El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67:285–289. doi:10.1002/jnr.10148
Ellison D, Love S, Chimelli LM, Harding B, Lowe JS, Vinters HV, Brandner S, Yong WH (2012) Neuropathology: a reference text of CNS pathology. Elsevier Health Sciences (3rd ed) USA pp 3–25
Ellman GL (1959) Tissue sulfhydryl group. Arch Biochem Biophys 74:214–226
Fendt M, Koch M (1999) Cholinergic modulation of the acoustic startle response in the caudal pontine reticular nucleus of the rat. Eur J Pharmacol 370:101–107. doi:10.1016/S0014-2999(99)00156-9
Flohe L, Otting F (1984) Superoxide dismutase assays. Methods Enzymol 105:93–104
Fredriksson A, Eriksson P, Archer T (1997) MPTP-induced deficits in motor activity: neuroprotective effects of the spin trapping agent alpha-phenyl-tert-butyl-nitrone (PBN). J Neural Trans 104:579–592. doi:10.1007/BF01291877
Goverdhan P, Sravanthi A, Mamatha T (2012) Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis 10:1–8. doi:10.1155/2012/974013
Greene JG, Greenamyre JT (1996) Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 48:613–634. doi:10.1016/0301-0082(96)00006-8
Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17:455–461. doi:10.1016/j.nbd.2004.07.006
Hanna DM, Tadros MG, Khalifa AE (2015) ADIOL protects against 3-NP-induced neurotoxicity in rats: possible impact of its anti-oxidant, anti-inflammatory and anti-apoptotic actions. Prog Neuro-Psychopharmacol Biol Psychatry 3:36–51. doi:10.1016/j.pnpbp.2015.02.005
Hassel B, Sonnewald U (1995) Selective inhibition of the tricarboxylic acid cycle of GABAergic neurons with 3-nitropropionic acid in vivo. J Neurochem 65:1184–1191. doi:10.1046/j.1471-4159.1995.65031184.x
He F, Zhang S, Qian F, Zhang C (1995) Delayed dystonia with striatal CT lucencies induced by a mycotoxin 3-nitropropionic acid. Neurology 45:2178–2183
Jones TC, Hunt RD (1983) Veterinary pathology. Lea & Febiger. Inc., Philadelphia, pp 904–905
Jones CK, Shannon HE (2000) Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. Eur J Pharmacol 391:105–112. doi:10.1016/S0014-2999(00)00055-8
Kiray M, Bagriyanik HA, Pekcetin C, Ergur BU, Uysal N (2008) Protective effects of deprenyl in transient cerebral ischemia in rats. Chin J Physiol 51:275–281
Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (−) deprenyl. Mech Ageing Dev 46:237–262
Knoll J (1998) (−)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82:57–66
Kodsi MH, Swerdlow NR (1997) Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease. Neurosci Lett 231:103–107. doi:10.1016/S0304-3940(97)00482-5
Kumar P, Kumar A (2008) Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid-induced behavioral alterations and oxidative stress in rats. Pharmacol Rep 60:706–715
Kumar P, Kumar A (2009a) Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunction in rat brain. Prog Neuro-Psychopharmacol Biol Psychiatry 33:100–108. doi:10.1016/j.pnpbp.2008.10.013
Kumar P, Kumar A (2009b) Protective effects of epigallocatechin gallate following 3-nitropropionic acid-induced brain damage: possible nitric oxide mechanisms. Psychopharmacology (Berl) 207:257–270. doi:10.1007/s00213-009-1652-y
Kumar P, Kumar A (2010) Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington’s like symptoms in rats: possible role of nitric oxide. Behav Brain Res 6107:1–9. doi:10.1016/j.bbr.2009.08.028
La Fontaine M, Geddes J, Banks A, Butterfield DA (2000) Effect of exogenous and endogenous antioxidants on 3-nitropropionic acid- induced oxidative stress and striatal lesions: insights into Huntington’s disease. J Neurochem 75:1709–1715. doi:10.1046/j.1471-4159.2000.0751709.x
Langston JW, Tanner CM (2000) Selegiline and Parkinson’s disease: it’s de’ja’Vu-again. Neurology 55:1770–1771. doi:10.1212/WNL.55.12.1770
Lee WT, Chang C (2004) Magnetic resonance imaging and spectroscopy in assessing 3-nitopropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog Neurobiol 72:87–110. doi:10.1016/j.pneurobio.2004.02.002
Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492–498. doi:10.1017/S0317167100032212
Magyar K, Haberle D (1999) Neuroprotective and neuronal rescue effects of selegiline. Neurobiology (Bp) 7:175–190. doi:10.1002/jnr.10148
Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E (2004) Pharmacological aspects of (−)-deprenyl. Curr Med Chem 11:2017–2031. doi:10.2174/0929867043364793
Mahdy HM, Tadros MG, Mohamed MR, Karim AM, Khalifa AE (2011) The effect of Ginkgo biloba extract on 3-nitropropionic acid-induced neurotoxicity in rats. Neurochem Int 59:770–778. doi:10.1016/j.neuint.2011.07.012
Maragos WF, Tillman PA, Chesnut MD, Jakel RJ (1999) Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834:168–172. doi:10.1016/S0006-8993(99)01487-0
Matsubara K, Senda T, Uezono T et al (2001) L-deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP, and carbolinium: a microdialysis study in rats. Neurosci Lett 302:65–68. doi:10.1016/S0304-3940(01)01601-9
Menze ET, Tadros MG, Abdel-Tawab AM, Khalifa AE (2012) Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats. Neurotoxicology 33:1265–1275. doi:10.1016/j.neuro.2012.07.007
Menze ET, Esmat A, Tadros MG, Abdel-Naim AB, Khalifa AE (2015) Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties. PLoS One 12:1–21. doi:10.1371/journal.pone.0117223
Moncada S, Bolaños JP (2006) Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 97:1676–1689. doi:10.1111/j.1471-4159.2006.03988.x
Montilla P, Túnez I, Muñoz MC et al (2004) Effect of glucocorticoids on 3-nitropropionic acid-induced oxidative stress in synaptosomes. Eur J Pharmacol 488:19–25. doi:10.1016/j.ejphar.2004.02.004
Muralikrishnan D, Samantaray S, Mohanakumar KP (2003) D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse 50:7–13. doi:10.1002/syn.10239
Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow C (1997) L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 68:33–39
Nakatsu K, Owen JA (1980) A microprocessor-based animal monitoring system. J Pharmacol Methods 3:71–82. doi:10.1016/0160-5402(80)90066-2
Ott DA, Mandel RJ (1995) Amphetamine sensitivity in open-field activity versus the prepulse inhibition paradigm. Brain Res Bull 37:219–222. doi:10.1016/0361-9230(94)00276-7
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, compact, 3rd edn. Academic press, Sydney
Pouzet B, Feldon J, Veenman CL, Yee BK, Richmond M, Nicholas J, Rawlins P, Weiner I (1999) The effects of hippocampal and fimbria-fornix lesions on prepulse inhibition. Behav Neurosci 113:968–981. doi:10.1037/0735-7044.113.5.968
Qin F, Shite J, Mao W, Liang C (2003) Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur J Pharmacol 461:149–158. doi:10.1016/S0014-2999(03)01306-2
Rehman MU, Tahir M, Khan AQ, Khan R, Lateef A, Hamiza OO, Qamar W, Sultana S (2013) Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-KB. Toxicol Lett 216:146–158. doi:10.1016/j.toxlet.2012.11.013
Reijmers LG, Vanderheyden PM, Peeters BW (1995) Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur J Pharmacol 272:131–138. doi:10.1016/0014-2999(94)00629-L
Rigdon GC, Weatherspoon JK (1992) 5-Hydroxytryptamine 1A receptor agonists block prepulse inhibition of the acoustic startle response. J Pharmacol Exp Ther 263:486–493
Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83–98. doi:10.1016/S1474-4422(10)70245-3
Schulz JB, Henshaw DR, Macgarvey U, Beal MF (1996) Involvement of oxidative stress in 3-NP neurotoxicity. Neurochem Int 29:167–171. doi:10.1016/0197-0186(95)00122-0
Seaman RL (2000) Effects of acute systemic 3-nitropropionic acid administration on rat activity and acoustic startle. Neurosci Lett 280:183–186. doi:10.1016/S0304-3940(00)00790-4
Sharma SK, Carlson EC, Ebadi M (2003) Neuroprotective actions of selegiline in inhibiting 1-methyl, 4- phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytol 32:329–343. doi:10.1023/B:NEUR.0000011327.23739.1b
Shirai Y, Fujita Y, Hashimoto K (2012) Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. Clin Psychopharmacol Neurosci 10:94–98. doi:10.9758/cpn.2012.10.2.94
Simon L, Szilgyi G, Bori Z, Orbay P, Nagy Z (2001) (−)-Deprenyl attenuates apoptosis in experimental brain ischemia. Eur J Pharmacol 430:235–241. doi:10.1016/S0014-2999(01)01375-9
Sipes TE, Geyer MA (1997) DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 761:97–104. doi:10.1016/S0006-8993(97)00316-8
Sultana S, Verna K, Khan R (2012) Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative sress. J Pharm Pharmacol 64:872–881. doi:10.1111/j.2042-7158.2012.01470.x
Suuronen T, Kolehmainen P, Salminen A (2000) Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem Pharmacol 59:1589–1595. doi:10.1016/S0006-2952(00)00282-3
Swerdlow NR, Braff DL, Geyer MA (1991) GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Res 532:146–150. doi:10.1016/0006-8993(90)91754-5
Swerdlow NR, Caine SB, Braff DL, Geyer MA (1992) Neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications. J Psychopharmacol 6:176–190. doi:10.1177/026988119200600210
Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR (1995) Impaired prepulse inhibition of acoustic and tactile startle in patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 58:192–200. doi:10.1136/jnnp.58.2.192
Swerdlow NR, Taaid N, Oostwegel JL, Randolph E, Geyer MA (1998) Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav Pharmacol 9:389–396
Swerdlow NR, Braff DL, Geyer MA (2000) Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 111:185–204
Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156:194–215
Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K (2001) Antiapoptotic and apoptotic action of (−)-deprenyl and its metabolites. J Neural Transm 108:25–33. doi:10.1007/s007020170094
Tadros MG, Khalifa AE, Abdel-Naim AB, Arafa HM (2005) Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington’s disease phenotype. Pharmacol Biochem Behav 82:574–582. doi:10.1016/j.pbb.2005.10.018
Takahata K, Shimazu S, Katsuki H, Yoneda F, Akaike A (2006) Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J Neural Transm 113:151–158. doi:10.1007/s00702-005-0309-1
Tatton WG, Chalmers-Redman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (−) deprenyl- related compounds in controlling neurodegeneration. Neurology 47:171–183. doi:10.1212/WNL.47.6
Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for Deprenyl in MPTP-parkinsonism. J Neurosci Res 30:666–672. doi:10.1002/jnr.490300410
Tatton WG, Wadia JS, Ju WYL, Chalmers-Redman RME, Tatton NA (1996) (−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm 48:45–59. doi:10.1007/978-3-7091-7494-4_5
Thomas CE, Huber EW, Ohlweiler DF (1997) Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates. Free Radic Biol Med 22:733–737. doi:10.1016/S0891-5849(96)00402-9
Tietz NW (1987) Fundamentals of clinical chemistry, 3rd edn. Saunders, W.B, Philadelphia, p 692
Tunez I, Montilla P, Muñoz MC, Feijóo M, Salcedo M (2004) Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington’s disease. J Pineal Res 37:252–256. doi:10.1111/j.1600-079X.2004.00163.x
Tunez I, Tasset I, Perez-De La Cruz V, Santamaria A (2010) 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington’s disease: past, present and future. Molecules 15:878–916. doi:10.3390/molecules15020878
Uchiyama M, Mihara M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86:271–278. doi:10.1016/0003-2697(78)90342-1
Villara’n RF, Toma’s-Camardiel M, de Pablos RM, Santiago M, Herrera AJ, Navarro A, Machado A, Cano J (2008) Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. Neurotoxicology 29:244–258. doi:10.1016/j.neuro.2007.11.001
Vis JC, Verbeek MM, De Waal RM, Ten Donkelaar HJ, Kremer HP (1999) 3-Nitropropionic acid induces a spectrum of Huntington’s disease-like neuropathology in rat striatum. Neuropathol Appl Neurobiol 25:513–521. doi:10.1046/j.1365-2990.1999.00212.x
Wadia JS, Chalmers-Redman RM, Ju WJ, Carlile GW, Phillips JL, Fraser AD, Tatton WG (1998) Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (−)-deprenyl. J Neurosci 18:932–947
Wu RM, Chiueh CC, Pert A, Murphy DL (1993) Apparent antioxidant effect of L- deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 243:241–247. doi:10.1016/0014-2999(93)90181-G
Yang L, Calingasan NY, Chen J, Ley JJ, Becker DA, Beal MF (2005) A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp Neurol 191:86–93. doi:10.1016/j.expneurol.2004.07.012
Zajaczkowski W, Gorka Z (1993) The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats. Pol J Pharmacol 45:157–166
Zhang J, Forkstam C, Engel JA, Svensson L (2000) Role of dopamine in prepulse inhibition of acoustic startle. Psychopharmacology 149:181–188. doi:10.1007/s002130000369
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Electronic supplementary material
ESM 1
(DOC 31 kb)
About this article
Cite this article
Wahdan, S.A., Tadros, M.G. & Khalifa, A.E. RETRACTED ARTICLE: Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats. Naunyn-Schmiedeberg's Arch Pharmacol 390, 905–917 (2017). https://doi.org/10.1007/s00210-017-1392-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-017-1392-1